Pfizer Gets US FDA OK for Maternal RSV Vaccine Abrysvo

Pfizer said it got US FDA approval for Abrysvo, the company’s RSV vaccine, for pregnant individuals at 32 through 36 weeks gestational age.

• Intended to help protect infants at birth through six months of life
• NOTE: Pfizer Gets FDA OK for Abrysvo RSV Vaccine for Older Adults

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.